Your browser doesn't support javascript.
loading
Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies.
Yang, Ming-Chen; Wang, Chun-Chung; Tang, Wei-Chien; Chen, Kuan-Ming; Chen, Chu-Ying; Lin, Hsiao-Han; Hsieh, Yin-Cheng; Wang, Nan-Hsuan; Kuo, Yin-Chieh; Chu, Ping-Tzu; Tung, Hsin-Yi; Wu, Yi-Chen; Sun, Juo-Ling; Liu, Sheng-Yu; Li, Wan-Fen; Lee, Wei-Han; Lai, Jiann-Shiun; Chang, Michael; Lai, Ming-Tain.
Afiliação
  • Yang MC; Department of Translational Biology, R&D Division, OBI Pharma. Inc., Taipei, Taiwan.
  • Wang CC; Department of Pharmacology, Pharmacokinetics, and Toxicology, R&D Division, OBI Pharma. Inc, Taipei, Taiwan.
  • Tang WC; Department of Analytics, R&D Division, OBI Pharma. Inc., Taipei, Taiwan.
  • Chen KM; Department of CMC, R&D Division, OBI Pharma. Inc., Taipei, Taiwan.
  • Chen CY; Department of Biologics Discovery, R&D Division, OBI Pharma. Inc., Taipei, Taiwan.
  • Lin HH; Department of CMC, R&D Division, OBI Pharma. Inc., Taipei, Taiwan.
  • Hsieh YC; Department of CMC, R&D Division, OBI Pharma. Inc., Taipei, Taiwan.
  • Wang NH; Department of Analytics, R&D Division, OBI Pharma. Inc., Taipei, Taiwan.
  • Kuo YC; Department of Biologics Discovery, R&D Division, OBI Pharma. Inc., Taipei, Taiwan.
  • Chu PT; Department of Pharmacology, Pharmacokinetics, and Toxicology, R&D Division, OBI Pharma. Inc, Taipei, Taiwan.
  • Tung HY; Department of Analytics, R&D Division, OBI Pharma. Inc., Taipei, Taiwan.
  • Wu YC; Department of Analytics, R&D Division, OBI Pharma. Inc., Taipei, Taiwan.
  • Sun JL; Department of Analytics, R&D Division, OBI Pharma. Inc., Taipei, Taiwan.
  • Liu SY; Department of Biologics Discovery, R&D Division, OBI Pharma. Inc., Taipei, Taiwan.
  • Li WF; Department of Pharmacology, Pharmacokinetics, and Toxicology, R&D Division, OBI Pharma. Inc, Taipei, Taiwan.
  • Lee WH; Department of Analytics, R&D Division, OBI Pharma. Inc., Taipei, Taiwan.
  • Lai JS; Department of Biologics Discovery, R&D Division, OBI Pharma. Inc., Taipei, Taiwan.
  • Chang M; CEO Office, OBI Pharma. Inc., Taipei, Taiwan.
  • Lai MT; CSO Office, OBI Pharma. Inc., Taipei, Taiwan.
PLoS One ; 18(3): e0283473, 2023.
Article em En | MEDLINE | ID: mdl-36961826
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: ISCOMs / COVID-19 Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: ISCOMs / COVID-19 Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article